STRIDES PHARMA SCIENCE LIMITED — Board/Management Information 2025

Jan 30, 2025

==> picture [154 x 50] intentionally omitted <==

January 30, 2025

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.

Scrip Code: STAR

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Scrip Code: 532531

Dear Sirs,

Sub: Outcome of Board Meeting

We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, Board of Directors of the Company at their meeting held today i.e., January 30, 2025, have approved the following:

• 1) Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025 .

Mukta is a pharmaceutical industry leader, with more than three decades of experience in the business across the pharmaceutical value chain.

With this appointment, Five out of Eight Directors on Strides’ Board shall be Independent Directors, of which two are Woman Directors; And the Board composition demonstrates Strides’ commitment to Diversity & Inclusion.

• 2) Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective April 5, 2025.

Mr. Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on April 6, 2025.

Upon successful transition of executive responsibilities to Mr. Badree Komandur (who was appointed as Managing Director and Group CEO effective June 1, 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective April 5, 2025.

The above appointments are subject to approval of Members of the Company through Postal Ballot.

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations in relation to above is enclosed as an Annexure.

Board Meeting commenced at 11:30 hrs IST and ended at 13:10 hrs IST.

==> picture [500 x 48] intentionally omitted <==

==> picture [154 x 50] intentionally omitted <==

This is for your kind information and record purposes.

Thanks & regards, For Strides Pharma Science Limited,

Digitally signed by MANJULA R MANJULA R Date: 2025.01.30 13:14:44 +05'30' Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

Encl. as above

==> picture [500 x 48] intentionally omitted <==

==> picture [154 x 50] intentionally omitted <==

Disclosure pursuant to Regulation 30 of SEBI Listing Regulation

relating to Board & Management Changes

1) Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company

#		Details	Information of such event
1.		Reasons for change, viz., appointmen~~t,~~ ~~resignation, removal, death or otherwise~~	Ms. Mukta Arora (DIN: 07225715) is being appointed as Additional Director of the Company under the category of Independent Director effective February 1, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders’ approval. With over 30 years of experience in the global pharmaceutical industry and expertise across various functions, Mukta’s induction to the Board would be of immense benefit to the Company.
2.		Date of appointment/ re-appointment/ cessation and term of appointment/ re-appointment
3.		Brief profile (in case of appointment)	Mukta is a pharmaceutical industry leader, with experience of more than three decades in the business. Mukta is a gold medalist with Master of Pharmaceutics degree from DIPSAR with an Executive MBA from Indian Institute of Management, Bangalore. Mukta had been with Eli Lilly for majority of her career, in India and Europe, driving key business strategies and outcomes and building top notch brands and new businesses. In the last few years of her career, she has set up, scaled up and led two very successful Global capability center’s (“GCC”) for Eli Lilly and Elanco creating huge value for the organization. In her last role, as the Managing Director of Elanco GCC, she has brought in huge value to business via setup of various functional capabilities and by forging several Industry collaborations, alliances for accelerating drug discovery and development process, building robust supply chains, creating technology, Analytics and Digital hubs. Mukta has been part of the Pharmaceutical and GCC industry bodies and is an active speaker on corporate culture, DE&I, women leadership and talent development. She also enjoys her work in CSR space, with focus on children, health and education.
4.		Disclosure of relationships between directors (in case of appointment of a director)	None
5.		Other information pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and NSE Circular with ref. no. NSE/ CML/ 2018/ 24 dated June 20, 2018.	Mukta is not debarred from holding the office of Director pursuant to any SEBI Order or any other statutory authority.

==> picture [500 x 48] intentionally omitted <==

==> picture [154 x 50] intentionally omitted <==

• 2) Change in Designation of Mr. Arun Kumar from Executive Chairperson to Non – Executive Chairperson effective April 5, 2025.

#		Details		Information of such event
1.		Reasons for change, viz.,~~appointment,~~ ~~resignation, removal, death or~~otherwise		Mr. Arun Kumar (DIN: 00084845) is currently the Executive Chairperson of the Company. In May 22, 2024, as part of the strengthening the diversification of Board and succession planning, Arun transitioned to a Executive Chairperson position from Chairperson and Managing Director. Upon successful transition of executive responsibilities to Mr. Badree Komandur, who was appointed as Managing Director and Group CEO effective June 1, 2024, Arun has opted to assume the role of Non-Executive Chairperson effective April 5, 2025.
2.		Date of appointment/ re-appointment/ cessation and term of appointment/ re-appointment		Re-designation and appointment of Arun as Non-Executive Chairperson of the Company will be effective April 5, 2025.
3.		Brief profile (in case of appointment)		Not Applicable
4.		Disclosure of relationships between directors (in case of appointment of a director)
5.		Other information pursuant to BSE Circular with ref. no. LIST/ COMP/ 14/ 2018-19 and NSE Circular with ref. no. NSE/ CML/ 2018/ 24, both dated June 20, 2018.		Arun is not debarred from holding the office of Director pursuant to any SEBI Order or any other statutory authority.

==> picture [500 x 48] intentionally omitted <==

---